{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:56:56Z","timestamp":1793051816768,"version":"4.5.0"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012176","name":"Project 211","doi-asserted-by":"publisher","award":["D21004"],"award-info":[{"award-number":["D21004"]}],"id":[{"id":"10.13039\/501100012176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.micpath.2025.107861","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:48:26Z","timestamp":1751438906000},"page":"107861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Advances in the mechanisms of drug resistance of Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"206","author":[{"given":"Muhammad","family":"Sikandar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-3459","authenticated-orcid":false,"given":"Li","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2025.107861_bib1","series-title":"Global Tuberculosis Report","year":"2024"},{"key":"10.1016\/j.micpath.2025.107861_bib2","series-title":"Global Tuberculosis Report","year":"2010"},{"key":"10.1016\/j.micpath.2025.107861_bib3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.micpath.2025.107861_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.micpath.2025.107861_bib5","article-title":"Progress on the effects and underlying mechanisms of evodiamine in digestive system diseases, and its toxicity: a systematic review and meta-analysis","author":"Zhou","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.micpath.2025.107861_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12890-024-03119-1","article-title":"Assessing the quality of life in patients with drug-resistant tuberculosis: a cross-sectional study","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib8","series-title":"Global Tuberculosis Report","year":"2022"},{"key":"10.1016\/j.micpath.2025.107861_bib9","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ijid.2020.01.042","article-title":"MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network","volume":"92","author":"Migliori","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib10","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1074\/jbc.275.4.2520","article-title":"Action mechanism of antitubercular isoniazid - activation mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor","volume":"275","author":"Lei","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2025.107861_bib11","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1074\/jbc.275.4.2520","article-title":"Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor","volume":"275","author":"Lei","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2025.107861_bib12","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1021\/acs.chemrestox.7b00129","article-title":"Biotransformation of isoniazid by cytochromes P450: analyzing the molecular mechanism using density functional theory","volume":"30","author":"Jaladanki","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.micpath.2025.107861_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/20477724.2021.1928870","article-title":"Significance of the coexistence of non-codon 315 katG, inhA, and oxyR-ahpC intergenic gene mutations among isoniazid-resistant and multidrug-resistant isolates of Mycobacterium tuberculosis: a report of novel mutations","volume":"116","author":"Norouzi","year":"2022","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.micpath.2025.107861_bib14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/22221751.2020.1785334","article-title":"Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis","volume":"9","author":"Swain","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2025.107861_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102286","article-title":"Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan","volume":"138","author":"Khan","year":"2023","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107861_bib16","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1021\/acsomega.2c01036","article-title":"Deciphering isoniazid drug resistance mechanisms on dimeric Mycobacterium tuberculosis KatG via post-molecular dynamics analyses including combined dynamic residue network metrics","volume":"7","author":"Barozi","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.micpath.2025.107861_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-51562-6","article-title":"Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan","volume":"9","author":"Jabbar","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib18","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1128\/IAI.70.9.4955-4960.2002","article-title":"Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans","volume":"70","author":"Pym","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2025.107861_bib19","doi-asserted-by":"crossref","first-page":"1041.e1041","DOI":"10.1016\/j.cmi.2018.12.008","article-title":"Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates","volume":"25","author":"Islam","year":"2019","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.micpath.2025.107861_bib21","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1021\/acsomega.2c01036","article-title":"Deciphering isoniazid drug resistance mechanisms on dimeric mycobacterium tuberculosis KatG via post-molecular dynamics analyses including combined dynamic residue network metrics","volume":"7","author":"Barozi","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.micpath.2025.107861_bib28","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1039\/D1NP00067E","article-title":"Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi","volume":"39","author":"Kirsch","year":"2022","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/0300060521997596","article-title":"rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis isolates from rural areas of Zhejiang, China","volume":"49","author":"Zeng","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.micpath.2025.107861_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fmicb.2017.00711","article-title":"Interplay between mutations and efflux in drug resistant clinical isolates of Mycobacterium tuberculosis","volume":"8","author":"Machado","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib45","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/bab.2278","article-title":"The pncA gene mutations of Mycobacterium tuberculosis in multidrug\u2010resistant tuberculosis","volume":"69","author":"Mahmood","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.micpath.2025.107861_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.594171","article-title":"Characterization of pncA mutations and prediction of PZA resistance in Mycobacterium tuberculosis clinical isolates from chongqing, China","volume":"11","author":"Li","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib53","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41598-020-58635-x","article-title":"Structure guided prediction of Pyrazinamide resistance mutations in pncA","volume":"10","author":"Karmakar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib57","first-page":"891","article-title":"A new synthetic compound with antituberculous activity in mice: Ethambutol (dextro-2, 2\u2032-(ethylenediimino)-di-1-butanol)","volume":"83","author":"Thomas","year":"1961","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/fmb.11.123","article-title":"Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets","volume":"7","author":"Jankute","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib61","first-page":"6859","article-title":"Mycobacterium tuberculosis sub-lineage 4.2.2\/SIT149 as dominant drug-resistant clade in Northwest Ethiopia 2020-2022: In-silico whole-genome sequence analysis","volume":"16","author":"Mekonnen","year":"2023"},{"key":"10.1016\/j.micpath.2025.107861_bib69","series-title":"Mechanism of Thioamide Drug Action Against Tuberculosis and Leprosy","author":"Wang","year":"2007"},{"key":"10.1016\/j.micpath.2025.107861_bib74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/138920013804545151","article-title":"Metabolism of the antituberculosis drug ethionamide","volume":"14","author":"Vale","year":"2013","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.micpath.2025.107861_bib81","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/catal10050543","article-title":"Insights into the mechanism of ethionamide resistance in Mycobacterium tuberculosis through an in silico structural evaluation of EthA and mutants identified in clinical isolates","volume":"10","author":"de Souza","year":"2020","journal-title":"Catalysts"},{"key":"10.1016\/j.micpath.2025.107861_bib90","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41467-017-02118-7","article-title":"Inhibition of D-Ala: D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine","volume":"8","author":"Batson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.107861_bib93","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.3548","article-title":"Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance","volume":"48","author":"Desjardins","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.micpath.2025.107861_bib100","volume":"vol 61","author":"Nakatani","year":"2017"},{"key":"10.1016\/j.micpath.2025.107861_bib103","doi-asserted-by":"crossref","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","article-title":"Para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium Tuberculosis","volume":"288","author":"Zheng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2025.107861_bib105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/22221751.2019.1568179","article-title":"Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains","volume":"8","author":"Wei","year":"2019","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2025.107861_bib109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3389\/fcimb.2018.00399","article-title":"Methionine antagonizes para-Aminosalicylic acid activity via affecting folate precursor biosynthesis in Mycobacterium tuberculosis","volume":"8","author":"Howe","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib117","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/24206","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"396","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.107861_bib118","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/AAC.38.4.773","article-title":"Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations","volume":"38","author":"Takiff","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib78","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jgar.2020.02.019","article-title":"Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China","volume":"22","author":"Islam","year":"2020","journal-title":"J. Global Antimicrob. Resis."},{"key":"10.1016\/j.micpath.2025.107861_bib126","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jiac.2022.03.027","article-title":"Novel rrs mutations in second-line injectable drug-resistant clinical isolates of Mycobacterium tuberculosis from the Punjab province of Pakistan","volume":"28","author":"Sarwer","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib127","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1473-3099(21)00452-7","article-title":"Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study","volume":"22","author":"Penn-Nicholson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib138","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2180-14-165","article-title":"Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand","volume":"14","author":"Sowajassatakul","year":"2014","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib150","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s42003-023-05681-6","article-title":"Discovery and characterization of genes conferring natural resistance to the antituberculosis antibiotic capreomycin","volume":"6","author":"Toh","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.micpath.2025.107861_bib155","article-title":"Rapid detection of streptomycin-resistant Mycobacterium tuberculosis by rpsL-restriction fragment length polymorphism","volume":"6","author":"Karimi","year":"2017","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.micpath.2025.107861_bib157","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00284-022-03043-9","article-title":"Evaluation of mutations related to Streptomycin resistance in Mycobacterium tuberculosis clinical isolates","volume":"79","author":"Shafipour","year":"2022","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib163","series-title":"Tuberculosis Clinical Strains from Moscow","first-page":"10","article-title":"Genetic profile of linezolid-resistant M","author":"Ushtanit","year":"2021"},{"key":"10.1016\/j.micpath.2025.107861_bib173","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2666-5247(23)00002-2","article-title":"Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis","volume":"4","author":"Sonnenkalb","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.micpath.2025.107861_bib174","article-title":"Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107861_bib175","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3390\/jcm11071927","article-title":"Investigation of clofazimine resistance and genetic mutations in drug-resistant Mycobacterium tuberculosis isolates","volume":"11","author":"Park","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib178","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijantimicag.2008.04.004","article-title":"Linezolid for the treatment of infections caused by Gram-positive pathogens in China","volume":"32","author":"Lin","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2025.107861_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.655653","article-title":"Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination","volume":"12","author":"Du","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib180","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.01189-07","article-title":"In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants","volume":"52","author":"Hillemann","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib185","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.dib.2018.09.057","article-title":"Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis","volume":"20","author":"Ismail","year":"2018","journal-title":"Data Brief"},{"key":"10.1016\/j.micpath.2025.107861_bib188","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC-Antimicrob. Resis."},{"key":"10.1016\/j.micpath.2025.107861_bib189","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2025.107861_bib190","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","volume":"373","author":"Bloemberg","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib195","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1093\/jac\/dkad252","article-title":"Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates","volume":"78","author":"Mok","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib197","article-title":"Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis","author":"Rifat","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.micpath.2025.107861_bib205","first-page":"dlae086","article-title":"Antibiotic resistance in Mycobacterium tuberculosis alters tolerance to cell wall-targeting inhibitors","volume":"6","author":"Jowsey","year":"2024","journal-title":"JAC-Antimicrob. Resis."},{"key":"10.1016\/j.micpath.2025.107861_bib206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/acsinfecdis.9b00162","article-title":"Mechanisms of resistance associated with the inhibition of the dehydration step of type II fatty acid synthase in Mycobacterium tuberculosis","volume":"6","author":"Grzegorzewicz","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1171861","article-title":"In vitro modeling of isoniazid resistance mechanisms in Mycobacterium tuberculosis H37Rv","volume":"14","author":"Dokrungkoon","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib22","first-page":"1","article-title":"The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China","volume":"7","author":"Liu","year":"2018","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2025.107861_bib23","article-title":"Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis","volume":"54","author":"Maitre","year":"2024","journal-title":"Infect. Dis. News"},{"key":"10.1016\/j.micpath.2025.107861_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02968-23","article-title":"Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug resistant Mycobacterium tuberculosis","volume":"15","author":"Harrison","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2025.107861_bib25","series-title":"Genetics and Evolution of Infectious Diseases","first-page":"683","article-title":"Evolution, Phylogenetics, and Phylogeography of Mycobacterium tuberculosis complex","author":"Sola","year":"2024"},{"key":"10.1016\/j.micpath.2025.107861_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62946-8","article-title":"Large-scale statistical analysis of Mycobacterium tuberculosis genome sequences identifies compensatory mutations associated with multi-drug resistance","volume":"14","author":"Billows","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib27","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jiph.2018.04.005","article-title":"Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis","volume":"11","author":"Zaw","year":"2018","journal-title":"J. infect. Public Health"},{"key":"10.1016\/j.micpath.2025.107861_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fmicb.2015.00147","article-title":"Drug-resistant tuberculosis can be predicted by mycobacterial interspersed repetitive unit locus","volume":"6","author":"Yu-Feng","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fmicb.2016.00378","article-title":"Mycobacterial interspersed repetitive unit can predict drug resistance of Mycobacterium tuberculosis in China","volume":"7","author":"Cheng","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12864-023-09120-y","article-title":"The mutation rate of rpoB gene showed an upward trend with the increase of MIRU10, MIRU39 and QUB4156 repetitive number","volume":"24","author":"Su","year":"2023","journal-title":"BMC Genom."},{"key":"10.1016\/j.micpath.2025.107861_bib35","first-page":"1","article-title":"Diagnostic accuracy of Xpert MTB\/RIF Ultra for detecting pulmonary tuberculosis and rifampicin resistance: a systematic review and meta-analysis","author":"Wang","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-021-02246-7","article-title":"Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hainan, China: from 2014 to 2019","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib37","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/j.molcel.2022.06.034","article-title":"HeIR interacts with RNA polymerase to confer intrinsic rifamycin resistance","volume":"82","author":"Hurst-Hess","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.micpath.2025.107861_bib38","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1016\/j.molcel.2022.06.019","article-title":"HelR is a helicase-like protein that protects RNA polymerase from rifamycin antibiotics","volume":"82","author":"Surette","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.micpath.2025.107861_bib39","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1038\/s41467-020-20158-4","article-title":"Mycobacterial HelD is a nucleic acids-clearing factor for RNA polymerase","volume":"11","author":"Kouba","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.107861_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01885-20","article-title":"Low-level rifampin resistance and rpoB mutations in Mycobacterium tuberculosis: an analysis of whole-genome sequencing and drug susceptibility test data in New York","volume":"59","author":"Shea","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib41","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1016\/j.molcel.2022.06.019","article-title":"HelR is a helicase-like protein that protects RNA polymerase from rifamycin antibiotics","volume":"82","author":"Surette","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.micpath.2025.107861_bib42","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.2147\/IDR.S368444","article-title":"Pyrazinamide resistance and pncA mutation profiles in multidrug resistant Mycobacterium Tuberculosis","author":"Shi","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107861_bib43","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","article-title":"Treatment of tuberculosis. A historical perspective","volume":"12","author":"Murray","year":"2015","journal-title":"Annals Am. Thoracic Soc."},{"key":"10.1016\/j.micpath.2025.107861_bib44","volume":"vol 14","author":"Karmakar","year":"2019"},{"key":"10.1016\/j.micpath.2025.107861_bib46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/514096","article-title":"Recombinant Mycobacterium tuberculosis KatG (S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid","volume":"176","author":"Wengenack","year":"1997","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.micpath.2025.107861_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-3757-1","article-title":"Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania","volume":"19","author":"Juma","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12879-021-06306-1","article-title":"Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China","volume":"21","author":"Che","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.44.3.528-532.2000","article-title":"pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada","volume":"44","author":"Cheng","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.61","article-title":"Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis","volume":"3","author":"Shi","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.micpath.2025.107861_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02342-16","article-title":"Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis","volume":"61","author":"Yee","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S230774","article-title":"Detection of novel gene mutations associated with pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates in southern China","author":"Hameed","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107861_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gene.2016.01.024","article-title":"Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis","volume":"581","author":"Pandey","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.micpath.2025.107861_bib56","first-page":"dlae037","volume":"vol 6","author":"Carter","year":"2024"},{"key":"10.1016\/j.micpath.2025.107861_bib59","first-page":"910","volume":"vol 38","author":"Wang","year":"2016"},{"key":"10.1016\/j.micpath.2025.107861_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mimet.2017.12.003","article-title":"Molecular drug resistance profiles of Mycobacterium tuberculosis from sputum specimens using ion semiconductor sequencing","volume":"145","author":"Park","year":"2018","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.micpath.2025.107861_bib62","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/dkt448","article-title":"Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array","volume":"69","author":"Moure","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/951706","article-title":"Mutations found in embCAB, embR, and ubiA genes of ethambutol-sensitive and-resistant Mycobacterium tuberculosis clinical isolates from China","volume":"2015","author":"Xu","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.micpath.2025.107861_bib64","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1128\/AAC.03002-15","article-title":"Geographic differences in the contribution of ubiA mutations to high-level ethambutol resistance in Mycobacterium tuberculosis","volume":"60","author":"Lingaraju","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tube.2017.10.003","article-title":"Polymorphisms in Rv3806c (ubiA) and the upstream region of embA in relation to ethambutol resistance in clinical isolates of Mycobacterium tuberculosis from North India","volume":"108","author":"Giri","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107861_bib66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tube.2018.11.006","article-title":"Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates","volume":"114","author":"Tulyaprawat","year":"2019","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107861_bib67","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1128\/JB.188.8.2936-2944.2006","article-title":"Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo","volume":"188","author":"Sharma","year":"2006","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.micpath.2025.107861_bib68","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.2147\/IDR.S466371","article-title":"Different contributions of embB and ubiA mutations to variable level of ethambutol resistance in Mycobacterium tuberculosis isolates","author":"Nan","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107861_bib70","first-page":"1","article-title":"Experiments on the antituberculous activity of alpha-ethyl-thioisonicotinamide","volume":"79","author":"Rist","year":"1959","journal-title":"Am. Rev. Tuberc. Pulm. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib71","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1183\/13993003.00438-2016","article-title":"Efficacy and tolerability of ethionamide versus prothionamide: a systematic review","volume":"48","author":"Scardigli","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107861_bib72","doi-asserted-by":"crossref","first-page":"28326","DOI":"10.1074\/jbc.M003744200","article-title":"Activation of the pro-drug ethionamide is regulated in mycobacteria","volume":"275","author":"Baulard","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2025.107861_bib73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/antibiotics11020133","article-title":"Molecular determinants of ethionamide resistance in clinical isolates of Mycobacterium tuberculosis","volume":"11","author":"Ushtanit","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2025.107861_bib75","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3389\/fmicb.2017.02358","article-title":"Molecular characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in southern China","volume":"8","author":"Tan","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib76","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1128\/AAC.47.12.3799-3805.2003","article-title":"ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates","volume":"47","author":"Morlock","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib77","first-page":"3117","article-title":"Genetic characterization conferred Co-Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis isolates from Southern Xinjiang","volume":"16","author":"Cao","year":"2023","journal-title":"China (Q. Forecast Rep.)"},{"key":"10.1016\/j.micpath.2025.107861_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00616-19","article-title":"Bacterial genome-wide association identifies novel factors that contribute to ethionamide and prothionamide susceptibility in Mycobacterium tuberculosis","volume":"10","author":"Hicks","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2025.107861_bib80","series-title":"Molecular Genetics of Mycobacteria","first-page":"431","article-title":"Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities","author":"Vilch\u00e8ze","year":"2014"},{"key":"10.1016\/j.micpath.2025.107861_bib82","first-page":"131","article-title":"Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance","volume":"52","author":"Willand","year":"2019","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.micpath.2025.107861_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2022.107677","article-title":"Mutation in Eth A protein of Mycobacterium tuberculosis conferred drug tolerance against enthinoamide in Mycobacterium smegmatis mc2155","volume":"98","author":"Anand","year":"2022","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.micpath.2025.107861_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.959911","article-title":"mbtD and celA1 association with ethambutol resistance in Mycobacterium tuberculosis: a multiomics analysis","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01461-17","article-title":"Whole-transcriptome and-genome analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance","volume":"61","author":"de Welzen","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib86","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3389\/fmicb.2017.02358","article-title":"Molecular characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in Southern China","volume":"8","author":"Tan","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib87","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.2147\/IDR.S407525","article-title":"Genetic characterization conferred co-resistance to isoniazid and ethionamide in mycobacterium tuberculosis isolates from Southern Xinjiang, China","author":"Cao","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107861_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00616-19","article-title":"Bacterial genome-wide Association identifies novel factors that contribute to ethionamide and prothionamide susceptibility in Mycobacterium tuberculosis","volume":"10","author":"Hicks","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2025.107861_bib89","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107861_bib91","article-title":"Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us","volume":"12","author":"Intini","year":"2019","journal-title":"BMJ Case Reports CP"},{"key":"10.1016\/j.micpath.2025.107861_bib92","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40268-019-00281-4","article-title":"Amount of cycloserine emanating from terizidone metabolism and relationship with hepatic function in patients with drug-resistant tuberculosis","volume":"19","author":"Mulubwa","year":"2019","journal-title":"Drugs R&D"},{"key":"10.1016\/j.micpath.2025.107861_bib94","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/jac\/dkx316","article-title":"Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis","volume":"72","author":"Chen","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib95","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-019-12074-z","article-title":"Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes","volume":"10","author":"Evangelopoulos","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.107861_bib96","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/s41598-022-05524-0","article-title":"Whole-genome single nucleotide variant phylogenetic analysis of Mycobacterium tuberculosis lineage 1 in endemic regions of Asia and Africa","volume":"12","author":"Netikul","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02761-22","article-title":"Drug-resistant tuberculosis on the balkan peninsula: determination of drug resistance mechanisms with xpert MTB\/XDR and whole-genome sequencing analysis","volume":"11","author":"Truden","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107861_bib98","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.3548","article-title":"Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance","volume":"48","author":"Desjardins","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.micpath.2025.107861_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03422-24","article-title":"Cycloserine resistance among drug-resistant tuberculosis cases in Taiwan","author":"Wu","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107861_bib101","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2022.05.030","article-title":"Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentration","volume":"121","author":"Wu","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib102","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/IDR.S200697","article-title":"Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107861_bib104","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/JB.182.2.264-271.2000","article-title":"Mutational analysis of a role for salicylic acid in iron metabolism of Mycobacterium smegmatis","volume":"182","author":"Adilakshmi","year":"2000","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.micpath.2025.107861_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48940-5","article-title":"Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis","volume":"9","author":"Pandey","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11274-023-03834-7","article-title":"Whole genome sequencing reveals candidate genes involving in PAS resistance in M. Tuberculosis isolated from patients in Thailand","volume":"40","author":"Dokladda","year":"2024","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2025.107861_bib108","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1099\/mic.0.053983-0","article-title":"Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid","volume":"158","author":"Fivian-Hughes","year":"2012","journal-title":"Microbiology"},{"key":"10.1016\/j.micpath.2025.107861_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-022-00537-z","article-title":"Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations","volume":"21","author":"Wang","year":"2022","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.micpath.2025.107861_bib111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antibiotics13010013","article-title":"Competition between H4PteGlu and H2PtePAS Confers para-Aminosalicylic Acid Resistance in Mycobacterium tuberculosis","volume":"13","author":"Yu","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2025.107861_bib112","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiv149","article-title":"Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis","volume":"212","author":"Walter","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib113","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jgar.2020.03.008","article-title":"Prevalence and patterns of drug resistant pulmonary tuberculosis in India\u2014A systematic review and meta-analysis","volume":"22","author":"Lohiya","year":"2020","journal-title":"J. Global Antimicrob. Resis."},{"key":"10.1016\/j.micpath.2025.107861_bib114","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1016\/S2666-5247(22)00116-1","article-title":"Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study","volume":"3","author":"Finci","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.micpath.2025.107861_bib115","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107861_bib116","first-page":"1048","article-title":"Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial, the Lancet","volume":"7","author":"Tweed","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib119","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.str.2019.01.004","article-title":"Overall structures of Mycobacterium tuberculosis DNA gyrase reveal the role of a corynebacteriales GyrB-Specific insert in ATPase activity","volume":"27","author":"Petrella","year":"2019","journal-title":"Structure (London, England : 1993)"},{"key":"10.1016\/j.micpath.2025.107861_bib120","first-page":"795","volume":"vol 397","author":"Serwacki","year":"2024"},{"key":"10.1016\/j.micpath.2025.107861_bib121","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12890-020-1172-4","article-title":"Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients","volume":"20","author":"Kabir","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib122","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jgar.2023.05.001","article-title":"Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: a systematic review and meta-analysis","volume":"34","author":"An","year":"2023","journal-title":"J. Global Antimicrob. Resis."},{"key":"10.1016\/j.micpath.2025.107861_bib123","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1128\/AAC.00541-09","article-title":"Beijing genotype of 444 Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in 445 Vietnam","volume":"53","author":"Duong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib124","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","article-title":"Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin","volume":"62","author":"Nosova","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib125","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1093\/emboj\/18.11.3133","article-title":"Basis for prokaryotic specificity of action of aminoglycoside antibiotics","volume":"18","author":"Recht","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.micpath.2025.107861_bib128","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/clinids\/24.Supplement_1.S46","article-title":"The most frequent aminoglycoside resistance mechanisms\u2014changes with time and geographic area: a reflection of aminoglycoside usage patterns?","volume":"24","author":"Miller","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib129","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1128\/AAC.49.8.3192-3197.2005","article-title":"Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis","volume":"49","author":"Maus","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/JCM.01476-09","article-title":"Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis","volume":"48","author":"Via","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-021-00478-z","article-title":"Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis","volume":"20","author":"Ye","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.micpath.2025.107861_bib132","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1111\/febs.15582","article-title":"Role of post\u2010translational modifications in the acquisition of drug resistance in Mycobacterium tuberculosis","volume":"288","author":"Arora","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.micpath.2025.107861_bib133","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.molcel.2021.05.017","article-title":"Structural basis of transcriptional activation by the Mycobacterium tuberculosis intrinsic antibiotic-resistance transcription factor WhiB7","volume":"81","author":"Lilic","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.micpath.2025.107861_bib134","first-page":"193","volume":"vol 18","author":"Sirgel","year":"2012"},{"key":"10.1016\/j.micpath.2025.107861_bib135","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1128\/AAC.06003-11","article-title":"Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates","volume":"56","author":"Balganesh","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib136","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/med.21591","article-title":"Efflux pump inhibitors of clinically relevant multidrug resistant bacteria","volume":"39","author":"Lamut","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.micpath.2025.107861_bib137","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0966-842X(94)90622-X","article-title":"Resistance to drugs targeting protein synthesis in mycobacteria","volume":"2","author":"B\u00f6ttger","year":"1994","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2019.06.003","article-title":"Assessing capreomycin resistance on tlyA deficient and point mutation (G695A) Mycobacterium tuberculosis strains using multi-omics analysis","volume":"309","author":"Zhao","year":"2019","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib140","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkr109","article-title":"Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis","volume":"66","author":"Engstr\u00f6m","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib141","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3389\/fmicb.2019.01838","article-title":"Mutation and transmission profiles of second-line drug resistance in clinical isolates of drug-resistant Mycobacterium tuberculosis from Hebei Province, China","volume":"10","author":"Li","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib142","first-page":"405","article-title":"Characterization of a novel mutation in the overlap of tlyA and ppnK involved in capreomycin resistance in Mycobacterium","volume":"66","author":"Du","year":"2014","journal-title":"IUBMB Life"},{"key":"10.1016\/j.micpath.2025.107861_bib143","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jac\/dkp452","article-title":"Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal","volume":"65","author":"Perdigao","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib144","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diagmicrobio.2013.06.031","article-title":"Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China","volume":"77","author":"Du","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.molcel.2006.05.044","article-title":"Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2\u2032-O-methylations in 16S and 23S rRNAs","volume":"23","author":"Johansen","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.micpath.2025.107861_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105776","article-title":"Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin","volume":"117","author":"Xu","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.micpath.2025.107861_bib147","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/AAC.49.2.571-577.2005","article-title":"Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis","volume":"49","author":"Maus","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.113267","article-title":"Detection and various environmental factors of antibiotic resistance gene horizontal transfer","volume":"212","author":"Li","year":"2022","journal-title":"Environ. Res."},{"key":"10.1016\/j.micpath.2025.107861_bib149","first-page":"138","article-title":"Dual-Mechanism confers self-resistance to the antituberculosis antibiotic","volume":"17","author":"Pan","year":"2022","journal-title":"Capreomycin"},{"key":"10.1016\/j.micpath.2025.107861_bib151","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nm839","article-title":"Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States","volume":"9","author":"McCormick","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib152","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1128\/AAC.00102-13","article-title":"Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China","volume":"57","author":"Hu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123655","article-title":"High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis","volume":"10","author":"Pietersen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2025.107861_bib154","first-page":"269","article-title":"Streptomycin in experimental tuberculosis","volume":"52","author":"Feldman","year":"1945","journal-title":"Am. Rev. Tubercul."},{"key":"10.1016\/j.micpath.2025.107861_bib156","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01755-19","article-title":"Adduct formation of delamanid with NAD in mycobacteria","volume":"64","author":"Hayashi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib158","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1128\/AAC.40.4.1024","article-title":"Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities","volume":"40","author":"Sreevatsan","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib159","first-page":"2713","article-title":"The roles of rpsL, rrs, and gidB mutations in predicting streptomycin-resistant drugs used on clinical Mycobacterium tuberculosis isolates from Hebei Province, China","volume":"12","author":"Wang","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.micpath.2025.107861_bib160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tube.2018.05.003","article-title":"Characterization of mutations conferring streptomycin resistance to multidrug-resistant Mycobacterium tuberculosis isolates from Myanmar","volume":"111","author":"Oo","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107861_bib161","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jgar.2015.11.009","article-title":"Mutations in rrs, rpsL and gidB in streptomycin-resistant Mycobacterium tuberculosis isolates from Thailand","volume":"4","author":"Smittipat","year":"2016","journal-title":"J. Global Antimicrob. Resis."},{"key":"10.1016\/j.micpath.2025.107861_bib162","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/antibiotics10101169","article-title":"Characterization of mutations associated with streptomycin resistance in multidrug-resistant Mycobacterium tuberculosis in Zambia","volume":"10","author":"Bwalya","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2025.107861_bib164","series-title":"Emerging Paradigms in Delivery Systems for Antitubercular Therapy","first-page":"235","article-title":"Multidrug resistance complexity of mycobacterium tuberculosis and oxidative stress: the need for innovative drug delivery strategies","author":"Vigneswaran","year":"2025"},{"key":"10.1016\/j.micpath.2025.107861_bib165","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02770-23","article-title":"Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases","volume":"12","author":"Bhanushali","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107861_bib166","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/AAC.01814-10","article-title":"Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis","volume":"55","author":"Wong","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib167","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00106-24","article-title":"Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance","volume":"37","author":"Deventer","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2025.107861_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.659545","article-title":"Heterogeneous streptomycin resistance level among Mycobacterium tuberculosis strains from the same transmission cluster","volume":"12","author":"Rocha","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib169","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3390\/genes12122003","article-title":"The neglected contribution of streptomycin to the tuberculosis drug resistance problem","volume":"12","author":"Rocha","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.micpath.2025.107861_bib170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/1791013a0","article-title":"A new series of phenazines (rimino-compounds) with high antituberculosis activity","volume":"179","author":"Barry","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.107861_bib171","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/ciaa421","article-title":"Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial","volume":"73","author":"Iroh Tam","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.micpath.2025.107861_bib172","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36955-y","article-title":"Bedaquiline-and clofazimine-selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678","volume":"13","author":"Snobre","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib176","first-page":"34","article-title":"Detection of a historic reservoir of bedaquiline\/clofazimine resistance-associated variants in Mycobacterium","volume":"16","author":"Nimmo","year":"2024","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107861_bib177","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1128\/AAC.00871-09","article-title":"Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700)","volume":"53","author":"Locke","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib181","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.06227-11","article-title":"rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains","volume":"56","author":"Beckert","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib182","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/jac\/dkx094","article-title":"Examination of bedaquiline-and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region","volume":"72","author":"Zimenkov","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib183","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(14)60523-7","article-title":"The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities","volume":"385","author":"Mingote","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2025.107861_bib184","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98862-4","article-title":"Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid","volume":"11","author":"G\u00f3mez-Gonz\u00e1lez","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib186","first-page":"1","article-title":"In silico structural and mechanical insights into bedaquiline resistance associated with high-grade non-synonymous mutations in atpE, mmpR5, and pepQ","author":"Chakraborty","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.micpath.2025.107861_bib187","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2025.107861_bib191","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10096-019-03551-w","article-title":"Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis","volume":"38","author":"Wen","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib192","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01755-19","article-title":"Adduct Formation of Delamanid with NAD in mycobacteria","volume":"64","author":"Hayashi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002873","article-title":"The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011\u20132018","volume":"16","author":"Schuster Bruce","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.micpath.2025.107861_bib194","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tube.2017.12.006","article-title":"Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis","volume":"108","author":"Fujiwara","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2025.107861_bib196","volume":"vol 65","author":"Rifat","year":"2020"},{"key":"10.1016\/j.micpath.2025.107861_bib198","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2025.107861_bib199","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1038\/s41598-018-23110-1","article-title":"Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)","volume":"8","author":"Baptista","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib201","article-title":"Spontaneous mutational patterns and novel mutations for Delamanid resistance in","volume":"66","author":"Liu","year":"2022","journal-title":"Mycobacterium Tubercul."},{"key":"10.1016\/j.micpath.2025.107861_bib202","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00308-15","article-title":"Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis","volume":"59","author":"Haver","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib203","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/00003495-199243050-00003","article-title":"Drug treatment of tuberculosis\u20141992","volume":"43","author":"Davidson","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.micpath.2025.107861_bib204","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.01063-06","article-title":"EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets","volume":"51","author":"Dover","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib207","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1365-2958.2009.06604.x","article-title":"Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis","volume":"71","author":"Alahari","year":"2009","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029564","article-title":"The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes","volume":"6","author":"Cantaloube","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2025.107861_bib209","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41598-020-58967-8","article-title":"Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis","volume":"10","author":"Lefebvre","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2025.107861_bib210","first-page":"195","article-title":"Mechanisms of resistance associated with the inhibition of the dehydration step of type II fatty acid synthase in","volume":"6","author":"Grzegorzewicz","year":"2020","journal-title":"Mycobacterium Tubercul."},{"key":"10.1016\/j.micpath.2025.107861_bib211","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1017\/S095026882100279X","article-title":"Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance","volume":"150","author":"Wang","year":"2022","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.micpath.2025.107861_bib212","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01562-14","article-title":"Linking system-wide impacts of RNA polymerase mutations to the fitness cost of rifampin resistance in Pseudomonas aeruginosa","volume":"5","author":"Qi","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2025.107861_bib213","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2025.107861_bib214","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.aam9321","article-title":"Nucleic acid detection with CRISPR-Cas13a\/C2c2","volume":"356","author":"Gootenberg","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.micpath.2025.107861_bib215","article-title":"A complete high-quality MinION nanopore assembly of an extensively drug-resistant Mycobacterium tuberculosis Beijing lineage strain identifies novel variation in repetitive PE\/PPE gene regions","volume":"4","author":"Bainomugisa","year":"2018","journal-title":"Microb. Genom."},{"key":"10.1016\/j.micpath.2025.107861_bib216","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173508","article-title":"Transcriptome analysis of mycobacteria in sputum samples of pulmonary tuberculosis patients","volume":"12","author":"Sharma","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2025.107861_bib217","series-title":"Deeplex\u00ae Myc-TB - a New Mycobacterium tuberculosis Drug Resistance Prediction Assay","author":"screen","year":"2025"},{"key":"10.1016\/j.micpath.2025.107861_bib218","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","article-title":"Global Tuberculosis Report 2020\u2013Reflections on the Global TB burden, treatment and prevention efforts","volume":"113","author":"Chakaya","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107861_bib219","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib220","first-page":"211","article-title":"Justification for the use of animals","volume":"3","author":"Carbone","year":"2014","journal-title":"The IACUC Handbook"},{"key":"10.1016\/j.micpath.2025.107861_bib221","series-title":"A New Class of Antibiotics Delivers Promising Trial Results Against Tuberculosis","author":"Carvalho","year":"2022"},{"key":"10.1016\/j.micpath.2025.107861_bib222","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-021-01576-0","article-title":"Contezolid: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.micpath.2025.107861_bib223","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2017.12.017","article-title":"Short-term safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy Chinese subjects","volume":"40","author":"Wu","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.micpath.2025.107861_bib224","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02181-16","article-title":"Single-and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects","volume":"61","author":"Eckburg","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib225","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1265923","article-title":"Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review","volume":"10","author":"Wang","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.micpath.2025.107861_bib226","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5582\/ddt.2022.01025","article-title":"Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"16","author":"Yang","year":"2022","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.micpath.2025.107861_bib227","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00253-018-9518-z","article-title":"Ethambutol targets the glutamate racemase of Mycobacterium tuberculosis\u2014an enzyme involved in peptidoglycan biosynthesis","volume":"103","author":"Pawar","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2025.107861_bib228","article-title":"Inevitable future: space colonization beyond Earth with microbes first","volume":"95","author":"Lopez","year":"2019","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Ecol."},{"key":"10.1016\/j.micpath.2025.107861_bib229","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.05708-11","article-title":"SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis","volume":"56","author":"Tahlan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib230","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02399-20","article-title":"Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis","volume":"65","author":"Ngwalero","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib231","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107861_bib232","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S390187","article-title":"In vitro and intracellular antibacterial activity of sudapyridine (WX-081) against tuberculosis","volume":"16","author":"Xiao","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2025.107861_bib233","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01372-22","article-title":"In vitro activity of the sudapyridine (WX-081) against non-tuberculous mycobacteria isolated in Beijing, China","volume":"10","author":"Zhu","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.107861_bib234","article-title":"First-in-Human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021"},{"key":"10.1016\/j.micpath.2025.107861_bib235","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib236","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107861_bib237","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-021-21748-6","article-title":"Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2025.107861_bib238","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.micpath.2025.107861_bib239","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/psp4.12226","article-title":"Assessing pharmacodynamic interactions in mice using the multistate tuberculosis pharmacometric and general pharmacodynamic interaction models","volume":"6","author":"Chen","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.micpath.2025.107861_bib240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285063","article-title":"Phenotypic and genotypic drug susceptibility patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Central and Southern Ethiopia","volume":"18","author":"Tilahun","year":"2023","journal-title":"PLoS One"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025005868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025005868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T18:58:39Z","timestamp":1752001119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025005868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":238,"alternative-id":["S0882401025005868"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107861","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the mechanisms of drug resistance of Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107861"}}